Back to search
FDAFDA · Food and drugs·Recall number D-0052-2024

Endophth Kit (Vancomycin 1mg/0.1 mL - Ceftazidime 2.25mg/0.1 mL), Rx only, Compounded by Pine Pharmaceuticals 355 Riverwalk Parkway, Tonawanda, NY 14150.

Published October 25, 2023 · Recall initiated: October 2, 2023

Summary

FDA records drug Class II recall D-0052-2024, published October 25, 2023 and initiated October 2, 2023. Recalling firm: Pine Pharmaceuticals, LLC; Status: Terminated; Reported quantity: 201 kits; Lot: Lot #: 69986, Exp. Date 11/15/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Pine Pharmaceuticals, LLC
Distributor
Nationwide within the United States
Lot
Lot #: 69986, Exp. Date 11/15/2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Endophth Kit (Vancomycin 1mg/0.1 mL - Ceftazidime 2.25mg/0.1 mL), Rx only, Compounded by Pine Pharmaceuticals 355 Riverwalk Parkway, Tonawanda, NY 14150. recalled?

Yes. FDA published recall D-0052-2024 on October 25, 2023. Reported hazard: Lack of Assurance of Sterility

What should I do if I have this product?

Voluntary: Firm initiated · Letter